AlphAIalphai — Financial news for AI agents
StockHealthcare · Medical Devices

$DCTH

DELCATH SYSTEMS, INC.

Price · $DCTHvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $DCTH in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $DCTH in the last 30 days.

Top stories · $DCTHMore →
MAY 7·Stock TitanMed

A liver-targeted breast cancer procedure drew new data at ESMO

Delcath Systems announced new data from a retrospective analysis on percutaneous hepatic perfusion with melphalan (M-PHP) using the CHEMOSAT Hepatic Delivery System for liver-dominant metastatic breast cancer. The data, presented at the ESMO Breast Cancer Congress 2026, showed hepatic partial response in 60% of evaluable patients and highlighted safety considerations like blood transfusions and transient bone marrow suppression. This real-world evidence supports further evaluation of HEPZATO KIT and CHEMOSAT in this heavily pretreated patient population.

FEB 5·Markets Mojo

Delcath Systems Faces Valuation Shift Amidst Mixed Financial Indicators and Growth Trends

Delcath Systems, Inc., a microcap biopharmaceutical company, has seen its valuation grade shift from attractive to expensive due to changing financial metrics, despite reporting positive pre-tax and net profit growth over the past five quarters. The company faces a complex financial landscape with negative EV to EBIT and EV to EBITDA ratios, and its stock's technical trend has moved to mildly bearish. This re-evaluation highlights the evolving financial dynamics for Delcath Systems within the competitive biotechnology sector.

News on $DCTH

All news →